Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neurosc... ( SAN FRANCISCO and WASHINGTON Nov. 14 ...)

Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011

Date:11/14/2011

SAN FRANCISCO and WASHINGTON, Nov. 14, 2011 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that positive preclinical data for NKTR-192, a novel mu-opioid agonist, was presented at the 41st Annual Meeting of the Society for Neuroscience being held November 12-16, 2011 in Washington, DC. NKTR-192 is a new oral analgesic candidate being developed for the treatment of acute pain. It is designed to minimize the unwanted central nervous system (CNS) side effects observed with standard opioid therapies and to reduce abuse liability by slowing the rate of drug entry into the brain. NKTR-192 is a novel mu-opioid analgesic molecule that was created using Nektar's proprietary polymer conjugate technology and its differentiating properties are inherent to the design of its new molecular structure.

Approximately 140 million prescriptions are written annually in the U.S. for acute pain indications, such as muscle injuries, post-operative pain, and kidney stones.(1),(2) Although prescription opioids are considered the most effective treatment for moderate-to-severe pain, their abuse has been identified by the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) as a significant public health issue. The abuse properties of opioid drugs are believed to be related to their rapid rate of entry into the brain.(3)

"NKTR-192 is an exciting new opioid molecule that builds on Nektar's pain platform, which includes NKTR-181, our novel opioid for chronic pain, currently in Phase 1 development," said Rob Medve, M.D., Chief Medical Officer of Nektar Therapeutics. "NKTR-192 has the potential to offer highly effective short-acting pain relief with a wide therapeutic window, including reduced abuse liability and sedation. A new opioid analgesic with this compelling profile would be a major advance in th
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
2. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
3. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
4. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
5. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
6. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
7. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
8. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
9. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
10. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
11. Hydrocodone and Oxycodones Lead U.S. General Workforce Positives, Outranked Only by Marijuana, According to Quest Diagnostics Drug Testing Index™

Post Your Comments:

(Date:5/21/2013)... and TARRYTOWN, N.Y. , May ... SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... published online the positive Phase 2a study results of ... is an investigational monoclonal antibody targeting the alpha subunit ... signaling of both IL-4 and IL-13, drivers of Th2 ...

(Date:5/21/2013)... UNION CITY, Calif. , May 21, 2013 /PRNewswire/ ... manufacturing point-of-care blood analysis systems, announced today that ... will present at the Stifel Annual Dental & Veterinary ... ET. The conference will be held at Le Parker ... . About Abaxis Abaxis develops, ...

(Date:5/21/2013)... May 21, 2013 Reportlinker.com announces ... available in its catalogue: ... Scenario for Medical Devices in the US ... Changing Regulatory and Reimbursement ... Market Summary ...

Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7 Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4

[0] Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine [0] Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference [0] Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market

... HIGHLIGHTS:2011 Results (all percentages are to ... reported sales increased 11% to $626 million. Q3 sales grew ... sales growing organically by 4% and 2%, respectively. Recently completed ... exchange rates contributed an additional 5% to reported sales growth ...

... Botanic Pharmaceutical Inc. (NYSE AMEX: CBP ) ... distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ... recently hosted a technical exchange between 13 senior research ... and herbal medicine. China Botanic participated ...

Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81.China Botanic Hosts Technical Exchange for Industry Research Experts

(Date:5/21/2013)... 2013 Standard advice for mattress shoppers ... else. However given industry’s less than exceptional satisfaction ratings ... the internet, Consumer Mattress Reports sets out to revise ... Best Mattress .” , This article addresses several components ... that may not be readily apparent to many shoppers. ...

(Date:5/21/2013)... 2013 DISCcert has served the training ... use 17 DISC applications at the July 25 & ... , The July 25 & 26th DISC certification in ... of applying DISC. The time-tested, proven support materials will ... DISC training materials ; worksheets, handouts, learning ...

(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...

(Date:5/21/2013)... France: The Orsiro stent, which is a novel ... demonstrated non-inferiority to the Xience Prime everolimus-eluting stent ... lumen loss at nine months in the results ... today. , The BIOFLOW-II substudy used intravascular ultrasound ... assess neointimal hyperplasia and stent apposition at nine ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 Phoseon Technology ... at the 20th Annual IMI European Ink Jet ... proven market leader, Phoseon continues to invest in product ... the adoption of UV LED curing in printing applications. ... families on the market offering both air cooled and ...

Breaking Medicine News(10 mins):Health News:Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article 2 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3 Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2

[0] Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article [0] DISCcert Offers 17 Applications in Coming DISC Certification [0] Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants [0] Biodegradable stent proves non-inferior to drug-eluting stent [0] Phoseon Technology Presents the Leading UV LED Curing Solutions at IMI European Ink Jet Conference

... International Liver Congress 2009, the 44th annual meeting of the ... Journalist registrations are being accepted for International Liver Congress 2009, ... , Press registration is free of charge for all holders ... The official EASL press conference will be held from 13.15 ...

... A failing heart makes a lot of a hormone needed ... but not enough of the enzyme needed to activate it, ... College of Georgia researchers found people in heart failure have ... pro-atrial natriuretic peptide, a hormone made by heart muscle cells ...

... WASHINGTON, March 31 Jeffrey Levi, Ph.D., ... today before the U.S. House Energy and Commerce Committee,s ... Care Work for American Families: Protecting the Public Health." ... investing in prevention, and the importance of incorporating public ...

... March 31 The not-for-profit LENA Foundation ... Biennial Meeting of the Society of Research in Child ... Colorado, four talks and one poster will be presented ... http://www.newscom.com/cgi-bin/prnh/20090210/LA69114 )"This year,s SRCD is a great opportunity ...

... 31 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) ... Award" is a most coveted, prestigious award, and ... Science and Technological Development. Submitted with the award ... preliminary trial of their Ribavirin product, confirming its ...

... March 31 Five local organizations and,individuals committed ... cholesterol,in Hispanic communities were awarded 2009 Cheerios Angel ... Chosen from a winning pool of nominations, ... healthier lifestyles and provided excellent resources to help ...

Cached Medicine News:Health News:New tests provide new insight into why patients are in heart failure 2 Health News:New tests provide new insight into why patients are in heart failure 3 Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 2 Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 3 Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 4 Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 2 Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 3 Health News:Hard To Treat Diseases (HTDS) Best Technological Innovation Award 2009 2 Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 2 Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 3 Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 4

International Liver Congress 2009 New tests provide new insight into why patients are in heart failure Trust for America's Health Testifies before Congress on Building Prevention into Health Reform Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation Hard To Treat Diseases (HTDS) Best Technological Innovation Award 2009 Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S.

A gentle yet highly effective corneal rust ring remover with Alger brush of 1mm burr. Runs off 1 x AA battery, no switches, simply spin mandrel to operate....

Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....

Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings. Ophtho-burr handpiece only. Battery powered handpiece....

Katena ophthalmic burr for polishing pterygiums, includes one round diamond burr and has an storage case....

Medicine Products:

Alger Brush Mk II Diamond Burr 2.5mm (5085)Ophtho-Burr Katena Ophthalmic Burr